Health
Ultragenyx to lay off 20% of employees, scrap a Wilson disease gene therapy
After a whirlwind third quarter that saw two FDA approvals but a major setback in Angelman syndrome, Ultragenyx is laying off staff for the second time this year. The California biopharma
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 31-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Servier's $1.5B bet on Edgewise drug fails five months inThe muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial. The drug, called sevasemten, failed the primary and secondary endpoints in the GRAND CANYON pivotal ...Bourla expects no changes to MFN deals after midtermsPfizer CEO Albert Bourla said he doesn't expect likely Democratic gains in Congress to affect the pricing deals made between drug companies and the Trump White House. “I don't think that many things can move ...Post-Hoc Live: What the US midterm elections mean for biopharma🗳️ Live Wednesday at 1:30 pm ET! 🎙️ It’s Election Day in the US, and the results could have wide-ranging implications for biotech and pharma. Democratic control of Congress would mean ...The biggest conversations in health techTomorrow, I’ll hop on a plane for what has become my favorite day of the year. On Thursday, we’re hosting our second-ever Endpoints Health Tech Day, with a virtual daytime ...Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slidePfizer raised its 2026 financial guidance as strong growth in its oncology and migraine businesses helped it weather sharp sales drops in its Covid products. The company reported third-quarter sales and ...Novartis ends BioArctic pact; Two VC firms raise inaugural fundsPlus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug Leqembi. The…This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
